Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare, debilitating neuromuscular and neurological diseases. They focus on bringing life-changing treatments to patients, with a strong commitment to patient care, accessibility, and global expansion through strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
Catalyst Pharmaceuticals
Patents
Products
Amifampridine phosphate (oral tablets)
Oral small-molecule potassium-channel blocking agent developed and commercialized for symptomatic improvement of neuromuscular transmission in Lambert-Eaton myasthenic syndrome; supported by randomized clinical trials and regulatory filings.
Vamorolone (oral suspension)
Oral suspension formulation developed for treatment of Duchenne muscular dystrophy in pediatric patients, authorized for North American commercialization through a strategic collaboration.
Perampanel (commercial rights in U.S.)
Commercial rights acquisition and commercialization of an approved antiepileptic drug in multiple strengths and dosage forms for treatment of partial-onset and generalized tonic-clonic seizures in labeled age groups.
CPP-115 (investigational)
Early-stage clinical candidate under development for refractory infantile spasms (and potential other indications), with orphan designation in the U.S. and EU.
Generic vigabatrin development
Development program to create a generic version of an approved anticonvulsant, involving formulation and regulatory filing activities.
AGAMREE
AGAMREE is a corticosteroid with a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Amifampridine phosphate (oral tablets)
Oral small-molecule potassium-channel blocking agent developed and commercialized for symptomatic improvement of neuromuscular transmission in Lambert-Eaton myasthenic syndrome; supported by randomized clinical trials and regulatory filings.
Vamorolone (oral suspension)
Oral suspension formulation developed for treatment of Duchenne muscular dystrophy in pediatric patients, authorized for North American commercialization through a strategic collaboration.
Perampanel (commercial rights in U.S.)
Commercial rights acquisition and commercialization of an approved antiepileptic drug in multiple strengths and dosage forms for treatment of partial-onset and generalized tonic-clonic seizures in labeled age groups.
CPP-115 (investigational)
Early-stage clinical candidate under development for refractory infantile spasms (and potential other indications), with orphan designation in the U.S. and EU.
Generic vigabatrin development
Development program to create a generic version of an approved anticonvulsant, involving formulation and regulatory filing activities.
AGAMREE
AGAMREE is a corticosteroid with a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Services
Negotiation and execution of licensing and sublicensing agreements and strategic partnerships to expand product portfolio and geographic commercialization.
Sponsorship and operational support for clinical trials (Phase 1–3) including study design, site selection, monitoring and data collection for rare neuromuscular indications.
End-to-end launch services including payer engagement, patient assistance, and support services to facilitate patient access to therapies.
Provision of grants and support for investigator-led studies to advance clinical knowledge in targeted rare diseases.
Deployment of Medical Science Liaisons and medical affairs resources to support clinical education, investigator engagement and evidence dissemination.
Management of programs providing access to investigational medicines for patients who lack alternatives and meet program criteria.
Negotiation and execution of licensing and sublicensing agreements and strategic partnerships to expand product portfolio and geographic commercialization.
Sponsorship and operational support for clinical trials (Phase 1–3) including study design, site selection, monitoring and data collection for rare neuromuscular indications.
End-to-end launch services including payer engagement, patient assistance, and support services to facilitate patient access to therapies.
Provision of grants and support for investigator-led studies to advance clinical knowledge in targeted rare diseases.
Deployment of Medical Science Liaisons and medical affairs resources to support clinical education, investigator engagement and evidence dissemination.
Management of programs providing access to investigational medicines for patients who lack alternatives and meet program criteria.
Expertise Areas
- Clinical trial management for rare diseases
- Neuromuscular and neurological therapeutic development
- Regulatory strategy and submissions (FDA/EMA)
- CMC and formulation development for oral drugs
Key Technologies
- Randomized double-blind and withdrawal clinical trial designs
- Crossover clinical trial methodology
- Special Protocol Assessment (SPA)-guided trial design
- GMP-compliant manufacturing
News & Updates
Catalyst held an investor call to discuss plans to commercialize Firdapse® (amifampridine) 10 mg tablets, recently approved by the FDA for adults with Lambert-Eaton myasthenic syndrome.
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
The FDA approved Firdapse® (amifampridine) for treating LEMS, marking the first evidence-based medicine approved for this condition.
Catalyst announced the appointment of new leaders to its commercial team, including SVPs of Operations & Analytics, Sales & Marketing, and Directors of Patient Engagement and Services.
An article discussing the importance of partnerships between pharma and patient advocacy groups in rare disease treatment.
Daniel J. Brennan was appointed as Chief Commercial Officer to lead marketing, sales, and operations as Catalyst prepares for potential approval of Firdapse.
Catalyst submitted an NDA to the FDA for Firdapse® for treating LEMS, marking a significant regulatory milestone.
Catalyst held an investor call to discuss plans to commercialize Firdapse® (amifampridine) 10 mg tablets, recently approved by the FDA for adults with Lambert-Eaton myasthenic syndrome.
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)
The FDA approved Firdapse® (amifampridine) for treating LEMS, marking the first evidence-based medicine approved for this condition.
Catalyst announced the appointment of new leaders to its commercial team, including SVPs of Operations & Analytics, Sales & Marketing, and Directors of Patient Engagement and Services.
An article discussing the importance of partnerships between pharma and patient advocacy groups in rare disease treatment.
Daniel J. Brennan was appointed as Chief Commercial Officer to lead marketing, sales, and operations as Catalyst prepares for potential approval of Firdapse.
Catalyst submitted an NDA to the FDA for Firdapse® for treating LEMS, marking a significant regulatory milestone.